Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Background There is currently no Europe-wide consensus on the appropriate preanalytical
measures and workflow to optimise procedures for tissue-based molecular testing of non …

Over the past few years, there have been considerable advances in the treatments available
to patients with metastatic or locally advanced NSCLC, particularly those who have …

Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C.
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …

Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …

Background Patients with cancer have an increased risk of complications from SARS-CoV-2
infection. Vaccination to prevent COVID-19 is recommended, but data on the …

Background Stage IV non–small-cell lung cancer (NSCLC) patients with oligometastases (<
5 metastatic lesions) may experience long-term survival when all macroscopic tumor sites …

Introduction Improved outcome has been shown in patients with synchronous
oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of …

The worldwide incidence of pulmonary carcinoids is increasing, but little is known about
their molecular characteristics. Through machine learning and multi-omics factor analysis …

Purpose: Non-small-cell lung cancers harboring EML4-ALK rearrangements are sensitive to
crizotinib. However, despite initial response, most patients will eventually relapse, and …